Your session is about to expire
← Back to Search
FOLFOX Chemotherapy for Rectal Cancer
Study Summary
This trial is testing whether patients with locally advanced rectal cancer can be treated with chemotherapy alone, without radiation or surgery.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2020 Phase 3 trial • 567 Patients • NCT02923921Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I do not have any infections needing IV antibiotics.I do not have heart, liver, or kidney diseases that would prevent me from receiving chemotherapy.My cancer is at a specific stage and size.I can become pregnant and agree to use effective birth control during the study.I do not have severe numbness or pain in my hands or feet.My cancer has not spread to other parts of my body.My rectal cancer likely needs a specific type of surgery.I had a clotting issue more than 6 months ago but am on a stable blood thinner.My cancer is very close to the edge of the tissue removed during surgery.I plan to have children in the future.My cancer has spread to other parts of my body.My rectal cancer cannot be surgically removed due to its spread to nearby organs.I do not have any other active cancer.I have lower rectal cancer and cannot have surgery to save the sphincter.My cancer is a type of rectal cancer confirmed by a biopsy.I have never been treated with platinum-based chemotherapy.My cancer is at a specific stage, not the most advanced.I have not received any treatment for my rectal cancer.I haven't had cancer, except for certain skin, breast, bladder, or cervical cancers, in the last 3 years.I haven't been treated for any cancer in the last 3 years.I have never received radiation therapy to my pelvic area.My rectal cancer has come back or is not responding to treatment.I have had a heart attack, stroke, or similar event in the last 6 months.I was over 18 when I was diagnosed.I am not currently pregnant or breastfeeding.
- Group 1: mFOLFOX (5-Fluorouracil Leucovorin Oxaliplatin)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has the FOLFOX regimen been cleared by the FDA?
"FOLFOX's safety is supported by some data, but not to the same extent as a Phase 3 trial. Therefore, it received a score of 2."
Can new patients still join this clinical trial?
"Unfortunately, this trial is no longer seeking patients. The listing for this study was first posted on May 3rd 2019 but was edited most recently on June 9th, 2022. However, there are 321 other trials recruiting cancer of the rectum patients and 564 FOLFOX trials that still need participants."
To what medical conditions is FOLFOX most often given as a treatment?
"FOLFOX is a standard treatment for advanced esophageal cancers, but it has also been used to ameliorate other conditions like stage iii colon cancer and advanced gastric cancer."
How many people have been recruited for this research project?
"This research project is not looking for participants at the moment. The trial was initially posted on May 3rd, 2019 and updated last on June 9th, 2022. If you are interested in other studies, 321 trials related to cancer of the rectum are currently admitting patients and 564 studies involving FOLFOX are actively searching for candidates."
What other steps have been taken to study FOLFOX?
"At this moment, there are 564 active clinical trials investigating FOLFOX with 194 in Phase 3. While a portion of these research studies are based in Woolloongabba, Queensland, 25836 other sites around the world are also studying FOLFOX."
Share this study with friends
Copy Link
Messenger